Sudarshan Pharma Resubmits FY26 Financial Results After Discrepancies

Sudarshan Pharma Industries Ltd has resubmitted its audited standalone financial results for the half-year and financial year ended March 31, 2026. This follows an earlier communication regarding discrepancies in the previously submitted financial results for the same period. The company has adopted Indian Accounting Standards (Ind AS) voluntarily from April 1, 2025. The financial statements have been reviewed by the Audit Committee and approved by the Board of Directors, with the statutory auditors issuing an unmodified review opinion. The company is engaged in manufacturing APIs, jobwork, and trading in chemicals and solvents, operating in a single reportable segment.